MEDGF (Medacta Group) Loans Receivable: $0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEDGF Medacta Group SA MEDGF
71 GF Score
Price $160.00
GF Value $90.63
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Medacta Group Loans Receivable?

Medacta Group MEDGF +90.68% 71 Loans Receivable is $0.0 Mil as of Dec. 2025. GuruFocus rates MEDGF with a GF Score™ of 71/100 and a GF Value™ of $90.63 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Medacta Group's Loans Receivable for the quarter that ended in Dec. 2025 was $0.0 Mil.

Medacta Group Loans Receivable Historical Data

* Premium members only.

The historical data trend for Medacta Group's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medacta Group Loans Receivable Chart

Medacta Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Medacta Group Semi-Annual Data
Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEDGF
71GF Score
Medacta Group SA MEDGF
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medacta Group Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.0 Mil mean?
Medacta Group (MEDGF) has a Loans Receivable of $0.0 Mil as of Dec. 2025. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Medacta Group and its competitors.
Is Medacta Group's Loans Receivable too high?
Medacta Group's current Loans Receivable is $0.0 Mil. Overall, Medacta Group has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's Loans Receivable compare to ABT and SYK?
Medacta Group's Loans Receivable of $0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Medical Devices & Instruments company?
A good Loans Receivable depends on the Medical Devices & Instruments industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Medacta Group and its competitors. Medacta Group's current Loans Receivable is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (MEDGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $90.63, compared to a current price of $160.00 — trading 76.5% above its estimated fair value. The current Loans Receivable is $0.0 Mil. Medacta Group's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Medacta Group (MEDGF), the current Loans Receivable is $0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medacta Group (MEDGF) Overvalued in 2026?

Based on GuruFocus' analysis, Medacta Group stock appears to be overvalued. The current stock price of $160.00 is trading 76.5% above its estimated GF Value™ of $90.63. GuruFocus considers Medacta Group to be Significantly Overvalued.

Key valuation signals for MEDGF:

  • Loans Receivable: $0.0 Mil
  • GF Value™: $90.63 vs. price of $160.00 (76.5% above fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the MEDGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medacta Group Business Description

Address Strada Regina 34, Castel San Pietro, Ticino, CHE, 6874
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
71GF Score

Get the complete analysis for MEDGF

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$160.00
Price
$90.63
GF Value